<DOC>
	<DOCNO>NCT02704728</DOCNO>
	<brief_summary>The purpose study assess safety tolerability Bacteroides thetaiotaomicron ( Thetanix® ) ) capsule young people age 16 18 year stable Crohn 's disease .</brief_summary>
	<brief_title>Study Bacteroides Thetaiotaomicron Young People Aged 16 18 Years With Stable Crohn 's Disease</brief_title>
	<detailed_description>This study single ( Part A ) multiple ( Part B ) dose study . Following informed consent screening , 10 eligible subject receive single dose Thetanix placebo clinic . A Safety Review Committee review safety data Day 7 first ten subject determine appropriate continue Part B 10 subject receive 15 dos Thetanix placebo twice daily dose regimen 7.5 day . In part study , 8 10 subject randomly receive Thetanix 2 subject randomly receive placebo . Each dose consist three capsule . Subjects Part B receive first last dose clinic take 13 dos home . While home , subject require answer question health , record body temperature take capsule electronic diary . Subjects develop fever undergo assessment , include blood culture . Subjects provide stool sample analysis microbiota faecal calprotectin .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Subjects age 16 18 year inclusive , confirmed diagnosis Crohn 's disease currently clinical remission* opinion investigator otherwise healthy . 2 . Subjects able willing give write informed consent participate . If applicable , parent/carer may also give consent participation . 1 . Subjects pregnant breastfeeding . 2 . Subject experience exacerbation time screen time first dose . 3 . Subjects undergone previous surgery resection bowel . 4 . Subjects fistulisation . 5 . Subjects significant change immunemodulating maintenance medication 3 month prior screen and/or start dose . 6 . Subjects take systemic steroid last 3 month . 7 . Subjects unable take oral feeding . 8 . Subjects feed gastrostomy . 9 . Subjects nonfood dietary supplementation reason change within 1 month prior dose . 10 . Subjects receive monoclonal antibody 6 month prior dose . 11 . Subjects receive antibiotic probiotic dietary supplementation two week dose . Subjects receive food probiotic e.g . yoghurt permit volunteer study . 12 . Subjects receive exclusive enteral feeding complete course exclusive enteral feed 3 month prior dose . 13 . Subjects concomitant autoimmune disease . 14 . Female Subjects child bear potential unwilling use effective contraception sign consent form completion two period last dose . An effective method birth control define one result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilisation , implant , injectables , combine oral contraceptive , Intrauterine Device ( IUD ) , condom , occlusive cap ( cervical/vault cap ) spermicidal foam/gel/film/cream/pessary . True sexual abstinence acceptable line prefer usual lifestyle subject . 15 . Subjects clinically significantly , opinion investigator , elevate platelet , white cell count , Creactive protein , erythrocyte sedimentation rate ( ESR ) , low albumin haemoglobin . 16 . Subjects positive follow virus : HIV , hepatitis B hepatitis C. 17 . Subjects smoke cigarette use tobacco nicotine containing product , include ecigarettes . 18 . Subjects know sensitivity constituent investigational medicinal compound . 19 . Diastolic blood pressure &lt; 50 &gt; 90 mmHg , systolic blood pressure &lt; 100 &gt; 150 mmHg , pulse &lt; 40 &gt; 100 beat per minute ( bpm ) rest 5 minute . 20 . Subjects clinically significantly abnormal ECGs structural cardiac abnormality e.g . valvular heart disease , patent foramen ovale . 21 . BMI Z SCORE le 2.6 great 2.6 ( 0 ± 2.6 ) ; i.e . 2nd centile great 98th centile . 22 . Any condition , opinion Investigator , might interfere primary study objective . 23 . Subjects allergic metronidazole coamoxiclav</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>